SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
EOLS

Evolus, Inc. (NASDAQ:EOLS)

US · Delayed Price · Currency is USD
Also listed: 0K16.LHealthcare · Drug Manufacturers - Specialty & Generic
$6.52-$0.48 (-6.86%)
 
Market cap
$432M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 8, 2018
Website
Market Cap$431.55M-4.8%
Revenue (ttm)$325.47M+13.9%
Net Income-$31.11M+46.9%
EPS-$0.47+49.1%
Shares Out66.19M
PE Ration/a
Forward PE19.76
Dividendn/a
Ex-Dividend Daten/a
Volume813,646
Open$6.83
Previous Close$7.00
Day's Range$6.50 - $7.17
52-Week Range$3.86 - $9.31
Beta1.34
AnalystsBuy
Price Target$15.00(+130.06%)
Earnings DateMar 2, 2027

About EOLS

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Address
520 Newport Center Drive, Newport Beach, CA, 92660, US
Market Cap
432 million
Employees
353
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.84M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $16.00 (+126.3%)

2 firms rating EOLS in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From EOLS’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-6.86%
5 Days
-5.51%
1 Month
-11.89%
6 Months
+1.09%
1 Year
-4.82%

$EOLS stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in EOLS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by EOLS's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

EOLS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

EOLS Revenue by Segment or Geography

EOLS's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New EOLS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to EOLS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in EOLS

IWMiShares Russell 2000 ETF$10.86M
VTIVanguard Morningstar Total Stock Market ETF$8.95M
VXFVanguard Extended Market ETF$4.96M
IWOiShares Russell 2000 Growth ETF$3.97M
XPHState Street SPDR S&P Pharmaceuticals ETF$3.41M
VTWOVanguard Russell 2000 ETF$2.57M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from EOLS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
7
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 5
0255075100Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 24.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 5Sep 19Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

GLAMCorgi ETF Trust I - Corgi Beauty, Skincare & Aesthetics ETF3.01%
XPHState Street SPDR S&P Pharmaceuticals ETF0.65%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.16%
IWCiShares Micro-Cap ETF0.11%
PILLDirexion Daily Pharmaceutical & Medical Bull 3X ETF0.10%
IHEiShares U.S. Pharmaceuticals ETF0.09%
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETF0.07%
VMO.TOVanguard Global Momentum Factor ETF0.05%
IBBQInvesco Nasdaq Biotechnology ETF0.03%
BIBProShares Ultra Nasdaq Biotechnology0.02%
VHTVanguard Health Care ETF0.01%

Weight is the stock’s share of each fund’s holdings.